[1]
O'Malley PG, Arnold MJ, Kelley C, Spacek L, Buelt A, Natarajan S, Donahue MP, Vagichev E, Ballard-Hernandez J, Logan A, Thomas L, Ritter J, Neubauer BE, Downs JR. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals of internal medicine. 2020 Nov 17:173(10):822-829. doi: 10.7326/M20-4648. Epub 2020 Sep 22
[PubMed PMID: 32956597]
Level 1 (high-level) evidence
[2]
Strilchuk L, Tocci G, Fogacci F, Cicero AFG. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert opinion on pharmacotherapy. 2020 Apr:21(5):531-539. doi: 10.1080/14656566.2020.1714028. Epub 2020 Feb 8
[PubMed PMID: 32036729]
Level 3 (low-level) evidence
[3]
Koopal C, Marais AD, Visseren FL. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Current opinion in endocrinology, diabetes, and obesity. 2017 Apr:24(2):133-139. doi: 10.1097/MED.0000000000000316. Epub
[PubMed PMID: 28098593]
Level 3 (low-level) evidence
[4]
Rygiel K. Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies. Current cardiology reviews. 2018 Mar 14:14(1):67-76. doi: 10.2174/1573403X14666180123165542. Epub
[PubMed PMID: 29366425]
[5]
van Rosendael AR, van den Hoogen IJ, Gianni U, Ma X, Tantawy SW, Bax AM, Lu Y, Andreini D, Al-Mallah MH, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Conte E, Marques H, de Araújo Gonçalves P, Gottlieb I, Hadamitzky M, Leipsic JA, Maffei E, Pontone G, Shin S, Kim YJ, Lee BK, Chun EJ, Sung JM, Lee SE, Virmani R, Samady H, Sato Y, Stone PH, Berman DS, Narula J, Blankstein R, Min JK, Lin FY, Shaw LJ, Bax JJ, Chang HJ. Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition. JAMA cardiology. 2021 Nov 1:6(11):1257-1266. doi: 10.1001/jamacardio.2021.3055. Epub
[PubMed PMID: 34406326]
[6]
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18:139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10
[PubMed PMID: 30586774]
Level 1 (high-level) evidence
[7]
Amarenco P, Tonkin AM. Statins for stroke prevention: disappointment and hope. Circulation. 2004 Jun 15:109(23 Suppl 1):III44-9
[PubMed PMID: 15198966]
[8]
Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, Kastelein JJP, Hutten BA. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. The New England journal of medicine. 2019 Oct 17:381(16):1547-1556. doi: 10.1056/NEJMoa1816454. Epub
[PubMed PMID: 31618540]
[9]
McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. Journal of the American Heart Association. 2019 Dec 17:8(24):e013225. doi: 10.1161/JAHA.119.013225. Epub 2019 Dec 16
[PubMed PMID: 31838973]
[10]
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.). 2023 May 1:77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17
[PubMed PMID: 36727674]
[11]
Asleh R, Briasoulis A, Pereira NL, Boilson BA, Edwards BS, Adigun R, Maltais S, Daly RC, Lerman A, Kushwaha SS. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients. ESC heart failure. 2018 Dec:5(6):1118-1129. doi: 10.1002/ehf2.12329. Epub 2018 Jul 17
[PubMed PMID: 30019530]
[12]
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29:148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20
[PubMed PMID: 37471501]
Level 1 (high-level) evidence
[13]
Sirtori CR. The pharmacology of statins. Pharmacological research. 2014 Oct:88():3-11. doi: 10.1016/j.phrs.2014.03.002. Epub 2014 Mar 20
[PubMed PMID: 24657242]
[14]
Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian journal of endocrinology and metabolism. 2015 Sep-Oct:19(5):554-62. doi: 10.4103/2230-8210.163106. Epub
[PubMed PMID: 26425463]
[15]
Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or Lipophilic Statins? Frontiers in cardiovascular medicine. 2021:8():687585. doi: 10.3389/fcvm.2021.687585. Epub 2021 May 20
[PubMed PMID: 34095267]
[16]
Filppula AM, Hirvensalo P, Parviainen H, Ivaska VE, Lönnberg KI, Deng F, Viinamäki J, Kurkela M, Neuvonen M, Niemi M. Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins. Drug metabolism and disposition: the biological fate of chemicals. 2021 Aug:49(8):658-667. doi: 10.1124/dmd.121.000406. Epub 2021 May 27
[PubMed PMID: 34045219]
Level 2 (mid-level) evidence
[17]
Egom EE, Hafeez H. Biochemistry of Statins. Advances in clinical chemistry. 2016:73():127-68. doi: 10.1016/bs.acc.2015.10.005. Epub 2016 Jan 13
[PubMed PMID: 26975972]
Level 3 (low-level) evidence
[18]
Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. Journal of the American College of Cardiology. 2013 Jun 25:61(25):2495-502. doi: 10.1016/j.jacc.2013.02.058. Epub 2013 Apr 3
[PubMed PMID: 23563132]
[19]
Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB, American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 Nov 22:134(21):e468-e495
[PubMed PMID: 27754879]
Level 2 (mid-level) evidence
[20]
Stone NJ, Greenland P, Grundy SM. Statin Usage in Primary Prevention-Comparing the USPSTF Recommendations With the AHA/ACC/Multisociety Guidelines. JAMA cardiology. 2022 Oct 1:7(10):997-999. doi: 10.1001/jamacardio.2022.2851. Epub
[PubMed PMID: 35998005]
[21]
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Jun 25:73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003. Epub 2018 Nov 10
[PubMed PMID: 30423393]
Level 1 (high-level) evidence
[22]
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18:139(25):e1046-e1081. doi: 10.1161/CIR.0000000000000624. Epub 2018 Nov 10
[PubMed PMID: 30565953]
Level 1 (high-level) evidence
[23]
Kamal SM. Effects of single-dose morning and evening administration of pravastatin on antioxidant markers in cholesterol-fed rabbits. Journal of experimental pharmacology. 2011:3():51-8. doi: 10.2147/JEP.S19449. Epub 2011 May 12
[PubMed PMID: 27186110]
[24]
Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014 Apr 9:311(14):1406-15. doi: 10.1001/jama.2014.2630. Epub
[PubMed PMID: 24682252]
Level 1 (high-level) evidence
[25]
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10:140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17
[PubMed PMID: 30879355]
Level 1 (high-level) evidence
[26]
Mahabadi AA, Möhlenkamp S, Lehmann N, Kälsch H, Dykun I, Pundt N, Moebus S, Jöckel KH, Erbel R, Heinz Nixdorf Recall Study Investigators. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines. JACC. Cardiovascular imaging. 2017 Feb:10(2):143-153. doi: 10.1016/j.jcmg.2016.03.022. Epub 2016 Sep 21
[PubMed PMID: 27665163]
[27]
Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H, Daida H, Dobashi K, Hayashi T, Hori M, Matsuki K, Minamino T, Yokoyama S, Harada-Shiba M. Homozygous Familial Hypercholesterolemia. Journal of atherosclerosis and thrombosis. 2021 Jul 1:28(7):665-678. doi: 10.5551/jat.RV17050. Epub 2021 Apr 18
[PubMed PMID: 33867421]
[29]
Thomson MJ, Serper M, Khungar V, Weiss LM, Trinh H, Firpi-Morell R, Roden M, Loomba R, Barritt AS 4th, Gazis D, Mospan AR, Fried MW, Reddy KR, Lok AS. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Feb:20(2):458-460.e4. doi: 10.1016/j.cgh.2021.03.031. Epub 2021 Mar 26
[PubMed PMID: 33775894]
[30]
Bea S, Oh IS, Kim JH, Sinn DH, Chang Y, Ryu S, Shin JY. High-Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population-Based Cohort Study. Journal of the American Heart Association. 2023 Apr 18:12(8):e028310. doi: 10.1161/JAHA.122.028310. Epub 2023 Apr 17
[PubMed PMID: 37066797]
[31]
Francis P, Forman L. Use of Statins in Patients With and Without Liver Disease. Clinical liver disease. 2020 Jan:15(1):40-45. doi: 10.1002/cld.866. Epub 2020 Feb 25
[PubMed PMID: 32104577]
[32]
Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. American journal of nephrology. 2011:34(3):195-202. doi: 10.1159/000330355. Epub 2011 Jul 23
[PubMed PMID: 21791915]
[33]
Schneider MP, Hübner S, Titze SI, Schmid M, Nadal J, Schlieper G, Busch M, Baid-Agrawal S, Krane V, Wanner C, Kronenberg F, Eckardt KU. Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney international. 2015 Dec:88(6):1411-1418. doi: 10.1038/ki.2015.246. Epub 2015 Sep 2
[PubMed PMID: 26331409]
[34]
Esmeijer K, Dekkers OM, de Fijter JW, Dekker FW, Hoogeveen EK. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Scientific reports. 2019 Nov 12:9(1):16632. doi: 10.1038/s41598-019-53064-x. Epub 2019 Nov 12
[PubMed PMID: 31719617]
Level 1 (high-level) evidence
[35]
Aschenbrenner DS. Statins No Longer Contraindicated in Pregnancy. The American journal of nursing. 2021 Nov 1:121(11):22. doi: 10.1097/01.NAJ.0000798992.09378.14. Epub
[PubMed PMID: 34673690]
[39]
Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA. Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. Journal of the American College of Cardiology. 2016 Jul 19:68(3):252-260. doi: 10.1016/j.jacc.2016.04.054. Epub
[PubMed PMID: 27417002]
[40]
Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circulation research. 2019 Jan 18:124(2):328-350. doi: 10.1161/CIRCRESAHA.118.312782. Epub
[PubMed PMID: 30653440]
[41]
Brown AS, Watson KE. Statin Intolerance. Reviews in cardiovascular medicine. 2018:19(S1):S9-S19. doi: 10.3909/ricm19S1S0005. Epub
[PubMed PMID: 30207553]
[42]
Caughey GE, Gabb GM, Ronson S, Ward M, Beukelman T, Hill CL, Limaye V. Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. JAMA internal medicine. 2018 Sep 1:178(9):1224-1229. doi: 10.1001/jamainternmed.2018.2859. Epub
[PubMed PMID: 30073275]
[43]
Chee WJ, Abdullahi H, Chan Y, Rattle A, Snedden S, Junckerstorff R. Retrospective evaluation of statin prescription in the elderly. Internal medicine journal. 2018 Dec:48(12):1463-1471. doi: 10.1111/imj.13996. Epub
[PubMed PMID: 29869449]
Level 2 (mid-level) evidence
[44]
Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. The Annals of pharmacotherapy. 2012 Apr:46(4):549-57. doi: 10.1345/aph.1Q620. Epub 2012 Apr 3
[PubMed PMID: 22474137]
Level 3 (low-level) evidence
[45]
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet (London, England). 2016 Nov 19:388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8
[PubMed PMID: 27616593]
[46]
Ribe AR, Vestergaard CH, Vestergaard M, Pedersen HS, Prior A, Lietzen LW, Brynningsen PK, Fenger-Grøn M. Statins and Risk of Intracerebral Hemorrhage in Individuals With a History of Stroke. Stroke. 2020 Apr:51(4):1111-1119. doi: 10.1161/STROKEAHA.119.027301. Epub 2020 Mar 2
[PubMed PMID: 32114928]
[47]
Tiniakou E. Statin-Associated Autoimmune Myopathy: Current Perspectives. Therapeutics and clinical risk management. 2020:16():483-492. doi: 10.2147/TCRM.S197941. Epub 2020 May 27
[PubMed PMID: 32581543]
Level 3 (low-level) evidence
[48]
Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. The American journal of cardiology. 2004 Oct 1:94(7):935-8
[PubMed PMID: 15464682]
[49]
Ehelepola NDB, Sathkumara SMBY, Bandara HMPAGS, Kalupahana KLR. Atorvastatin-Diltiazem Combination Induced Rhabdomyolysis Leading to Diagnosis of Hypothyroidism. Case reports in medicine. 2017:2017():8383251. doi: 10.1155/2017/8383251. Epub 2017 Apr 11
[PubMed PMID: 28487744]
Level 3 (low-level) evidence
[50]
Wang YC, Hsieh TC, Chou CL, Wu JL, Fang TC. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. Medicine. 2016 Jan:95(2):e2487. doi: 10.1097/MD.0000000000002487. Epub
[PubMed PMID: 26765458]
[51]
Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. The Annals of pharmacotherapy. 2002 Oct:36(10):1546-9
[PubMed PMID: 12243603]
[52]
Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. Journal of clinical lipidology. 2022 Jul-Aug:16(4):361-375. doi: 10.1016/j.jacl.2022.05.068. Epub 2022 Jun 9
[PubMed PMID: 35718660]
[53]
Wilkins B, Hullikunte S, Simmonds M, Sasse A, Larsen P, Harding SA. Improving the Prescribing Gap For Guideline Recommended Medications Post Myocardial Infarction. Heart, lung & circulation. 2019 Feb:28(2):257-262. doi: 10.1016/j.hlc.2017.10.025. Epub 2017 Nov 14
[PubMed PMID: 29523466]
[54]
Lee JS, Gonzales R, Vittinghoff E, Corbett KK, Fleischmann KE, Sehgal N, Auerbach AD. Appropriate Reconciliation of Cardiovascular Medications After Elective Surgery and Postdischarge Acute Hospital and Ambulatory Visits. Journal of hospital medicine. 2017 Sep:12(9):723-730. doi: 10.12788/jhm.2808. Epub
[PubMed PMID: 28914276]
[55]
Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, Ting HH, Chan PS. Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011 Nov 29:124(22):2405-10. doi: 10.1161/CIRCULATIONAHA.111.038265. Epub 2011 Nov 7
[PubMed PMID: 22064595]
[56]
Coste J, Billionnet C, Rudnichi A, Pouchot J, Dray-Spira R, Giral P, Zureik M. Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France. European journal of preventive cardiology. 2019 Mar:26(5):512-521. doi: 10.1177/2047487318776831. Epub 2018 May 25
[PubMed PMID: 29799296]
[57]
Moctezuma-Velázquez C, Abraldes JG, Montano-Loza AJ. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. Current treatment options in gastroenterology. 2018 Jun:16(2):226-240. doi: 10.1007/s11938-018-0180-4. Epub
[PubMed PMID: 29572618]
[58]
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, ALLHAT Collaborative Research Group. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. JAMA internal medicine. 2017 Jul 1:177(7):955-965. doi: 10.1001/jamainternmed.2017.1442. Epub
[PubMed PMID: 28531241]
Level 1 (high-level) evidence
[59]
Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiotherapy Canada. Physiotherapie Canada. 2014 Spring:66(2):124-32. doi: 10.3138/ptc.2012-65. Epub
[PubMed PMID: 24799748]
Level 3 (low-level) evidence
[60]
Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Disease-a-month : DM. 2020 Aug:66(8):101015. doi: 10.1016/j.disamonth.2020.101015. Epub 2020 Jun 10
[PubMed PMID: 32532456]
[61]
Crnobrnja L, Metlapalli M, Jiang C, Govinna M, Lim AKH. The Association of Insulin-dextrose Treatment with Hypoglycemia in Patients with Hyperkalemia. Scientific reports. 2020 Dec 16:10(1):22044. doi: 10.1038/s41598-020-79180-7. Epub 2020 Dec 16
[PubMed PMID: 33328554]
[62]
Zhao TJ, Luo D, Jiang X, Tang F, Jiang H. Effect of Statins on Major Adverse Cardiovascular Events in Patients with Coronary Artery Spasm: A Meta-Analysis of the Asia Region. Cardiovascular therapeutics. 2023:2023():8807278. doi: 10.1155/2023/8807278. Epub 2023 Apr 27
[PubMed PMID: 37151221]
Level 1 (high-level) evidence
[63]
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine. 2008 Nov 20:359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9
[PubMed PMID: 18997196]
[64]
Chogtu B, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. World journal of diabetes. 2015 Mar 15:6(2):352-7. doi: 10.4239/wjd.v6.i2.352. Epub
[PubMed PMID: 25789118]
[65]
Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation. 2018 May 8:137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615. Epub
[PubMed PMID: 29735587]
Level 1 (high-level) evidence
[66]
Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2018 Oct 2:7(19):e009835. doi: 10.1161/JAHA.118.009835. Epub
[PubMed PMID: 30371340]
Level 1 (high-level) evidence
[67]
van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to improve adherence to lipid-lowering medication. The Cochrane database of systematic reviews. 2016 Dec 21:12(12):CD004371. doi: 10.1002/14651858.CD004371.pub4. Epub 2016 Dec 21
[PubMed PMID: 28000212]
Level 1 (high-level) evidence